Log in
|
Specification |
Details |
|
Drug Detected |
Tramadol |
|
Cutoff Level |
100 ng/mL |
|
Sample Type |
Human Urine |
|
Test Format |
Rapid Test Strip |
|
Time to Results |
Approximately 5 Minutes |
|
CLIA Status |
CLIA Waived |
|
Intended Use |
Professional Point-of-Care Use |
Using the test strip is quick and straightforward:
Remove the test strip from its sealed pouch and use it immediately.
Hold the strip by the labeled end and avoid touching the test membrane.
Dip the test strip vertically into the urine specimen for 10–15 seconds, ensuring the urine level does not exceed the MAX line.
Remove the strip and place it on a clean, flat, non-absorbent surface.
Allow the test to develop and read the results within 3–5 minutes. Do not interpret results after 10 minutes.
Following the recommended testing procedure helps ensure reliable and accurate preliminary screening results
Tramadol is a prescription opioid analgesic used to treat moderate to moderately severe pain. It works by binding to opioid receptors in the brain while also affecting serotonin and norepinephrine levels, helping reduce the perception of pain.
Although tramadol is commonly prescribed for pain management, it is classified as a controlled substance in many countries because of its potential for misuse, dependence, and abuse. Professional drug testing may therefore be required in healthcare, workplace, compliance, and forensic settings
When prescribed by a licensed healthcare provider, tramadol may be used to treat:
Moderate to moderately severe pain
Acute pain following injury or surgery
Chronic pain management
Musculoskeletal pain
Neuropathic pain in selected patients
Tramadol should only be taken as prescribed under medical supervision
Although tramadol is an effective prescription medication, misuse may occur when it is taken without a prescription, in higher doses than prescribed, or for non-medical purposes.
Misuse may increase the risk of:
Dependence
Withdrawal symptoms
Respiratory depression
Seizures
Overdose
Professional drug screening helps identify recent tramadol exposure in clinical monitoring, workplace testing, rehabilitation programs, and forensic investigations
The effects of tramadol vary depending on dosage, medical condition, and individual response. Common effects may include:
Pain relief
Relaxation
Drowsiness
Dizziness
Nausea
Constipation
Dry mouth
Sweating
Reduced alertness
Mild euphoria in some individuals
Higher doses or misuse may increase the risk of serious adverse effects, including respiratory depression and seizures
Tramadol is marketed under several prescription brand names, including:
Ultram
ConZip
Qdolo
Ryzolt (where available)
The Tramadol Drug Test Strips provide several benefits for professional drug screening:
Rapid preliminary results in approximately 5 minutes
100 ng/mL screening cutoff
High accuracy
CLIA Waived for professional point-of-care testing
Simple dip-and-read procedure
No laboratory equipment required
Easy interpretation of results
Suitable for routine and high-volume testing
Designed for healthcare, workplace, compliance, and forensic applications
For reliable performance:
Store the test strips according to the recommended storage conditions.
Keep each strip sealed in its original pouch until ready for use.
Use the strip immediately after opening the pouch.
Do not use the product after its expiration date.
Protect the test from excessive heat, humidity, and direct sunlight.
Handle urine specimens using appropriate laboratory safety procedures
The Tramadol Drug Test Strips provide preliminary qualitative screening results only.
A positive result indicates the possible presence of tramadol above the screening cutoff but does not determine the amount consumed, frequency of use, or level of impairment.
A negative result does not necessarily exclude tramadol use if the concentration is below the cutoff level or outside the detection window.
Individual metabolism, hydration, specimen quality, collection procedures, and testing conditions may influence test results.
Any preliminary positive result should be confirmed using Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) before legal, employment, medical, or administrative decisions are made
The Tramadol Drug Test Strip is designed to detect tramadol in human urine.
This test uses a 100 ng/mL cutoff level for detecting tramadol.
Results are available in approximately 5 minutes when the testing instructions are followed correctly.
Yes. The Tramadol Drug Test Strips are suitable for professional drug screening in healthcare facilities, workplaces, treatment centers, compliance programs, occupational health clinics, and forensic laboratories.
No. The test only detects the presence of tramadol above the screening cutoff. It cannot determine whether the medication was used as prescribed or misused. Clinical evaluation and professional judgment are required when interpreting results.
No. Although this product is CLIA Waived for professional point-of-care testing, it is not intended for medical diagnosis. It provides preliminary screening results only
The Tramadol Drug Test Strips provide a fast, accurate, and dependable solution for the preliminary detection of tramadol in human urine. Featuring a 100 ng/mL cutoff level, 5-minute results, and a simple dip-and-read format, these CLIA Waived test strips are designed for efficient professional point-of-care drug screening.
Ideal for clinics, treatment and rehabilitation centers, workplace drug testing programs, healthcare facilities, compliance monitoring, occupational health services, and forensic laboratories, the test delivers reliable preliminary results without the need for specialized laboratory equipment or technical training. Its high accuracy, straightforward operation, and rapid turnaround time make it an excellent choice for routine and high-volume tramadol screening.
As with all rapid immunoassay screening devices, any preliminary positive result should be confirmed using Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) before legal, employment, medical, or administrative decisions are made. The Tramadol Drug Test Strips are CLIA Waived for professional point-of-care use and are intended to provide preliminary qualitative screening results only. They are not intended for medical diagnosis or home use.
The Tramadol Drug Test Strips are rapid urine screening devices designed for the qualitative detection of tramadol in human urine. Using a simple dip-and-read format, these professional test strips provide preliminary results in approximately 5 minutes, making them an efficient solution for routine and high-volume drug screening.
Designed with a 200 ng/mL cutoff level, the Tramadol Drug Test Strips deliver dependable preliminary screening with high accuracy. The easy-to-use design requires no laboratory equipment or specialized training, allowing for fast and convenient on-site testing in professional environments.
These CLIA Waived test strips meet federal quality and performance standards for professional point-of-care testing. They are suitable for use in clinics, treatment centers, workplace drug testing programs, healthcare facilities, compliance monitoring, and forensic laboratories.
The Tramadol Drug Test Strips provide preliminary qualitative screening results only. Any preliminary positive result should be confirmed using a more specific laboratory confirmation method such as Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS).
This product is intended for professional use and is designed for point-of-care drug screening. It is not intended for medical diagnosis
Tramadol
Tramadol is generally detectable in urine for approximately 2–4 days after use. Detection time may vary depending on dosage, frequency of use, metabolism, hydration, age, kidney function, and overall health.
Individuals taking tramadol regularly may remain detectable for a longer period
This Tramadol Drug Test Strip uses a screening cutoff of:
Tramadol: 100 ng/mL
Samples at or above this concentration may produce a preliminary positive result and should be confirmed using an appropriate laboratory confirmation method
A colored line appears in both the Control (C) and Test (T) regions. Even if the Test (T) line appears faint, the result should be interpreted as negative, indicating that the concentration of tramadol is below the 100 ng/mL cutoff level
A colored line appears only in the Control (C) region, while no visible line appears in the Test (T) region. This indicates that tramadol may be present at or above the 100 ng/mL screening cutoff.
Because this device provides preliminary screening results only, all positive results should be confirmed using a more specific laboratory method such as Gas Chromatography–Mass Spectrometry (GC-MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
If the Control (C) line does not appear, the test result is invalid, regardless of whether a Test line is visible. This may occur due to insufficient specimen volume, improper testing procedure, or a defective test strip.
Repeat the test using a new strip and a fresh urine specimen
Tramadol Drug Test Strips 200 ng/mL | Serenity SM-DOA-TRASP 25/Box
Sign up for updates from leading retailers
